Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia.

Front Immunol · 2023 · PMC10679681 · PMID 38022523

Europe PMC DOI

hedged sentence

0.0750

closest p · 1.5× alpha

0.0750

boldest claim

The sentences

showed a trendp = 0.075so close (0.05 < p ≤ 0.1)

Treatment with mSCF CAR did not result in a significant survival benefit under the conditions tested, whereas hSCF sBite γδ T cells showed a trend towards survival enhancement ( Figure 8E , p = 0.075).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.